#Japan #Tokyo #AI Data #Drug Discovery #Biotech Forum

The AI Agents × AX Forum: Drug Discovery & Biotechnology

On August 20th, 2026, Japan's leading AI Data Company hosted a hybrid forum titled "AI Agents × AX Forum: Growth Strategies Across 17 Fields - Drug Discovery & Biotechnology Edition" at the Nihon Keizai Conference Room in Otemachi, Tokyo. This event aimed to explore the application of AI in the drug discovery sector and promote AI Transformation (AX).

As part of Japan's growth strategy, drug discovery and advanced medical care are crucial for national security, economic stability, and overall growth. In an era poised for a significant shift likened to a second industrial revolution, the future of the drug and biotech industries remains a topic of concern. Attendees gathered to learn how AI technology might shape these industries moving forward.

During the forum, industry experts presented on topics including drug discovery, genomic medicine, intellectual property, and the integration of AI and data solutions. A particular focus was placed on how disconnected corporate data could be unified through AI agents to promote more informed strategic decisions related to research and development.

Special Event Highlights

Attendees who participated in-person enjoyed exclusive benefits such as:

• - Networking opportunities with speakers and participating companies.
• - A free trial of "AI Kongming on IDX."

Exclusive Agenda Insights

The forum included key sessions such as:

1. AI Civilization and the Evolution of Japan's Drug and Biotechnology Industries
Presented by Takahiro Sasaki, this opening session set the stage by discussing how the current era of AI is a transformative point reminiscent of the past industrial revolutions. The session defined the differences between AI Ready and AI Native, highlighting the importance of integrating enterprise intelligence into business strategies moving forward.

2. Current State of the Pharmaceutical Industry
Delivered by Taka Horii, insights were provided on the structural changes imposed on the industry due to various factors such as aging populations, diverse modalities, and financial strains. The address also strategized on retaining core competencies amidst these rapid transformations driven by AI.

3. Implementing AI Data Platforms
Daisuke Shida presented on the capabilities of the AI Data Platform, which consolidates critical data across various sectors of the company, creating a robust Enterprise Intelligence framework. This session included demonstrations of how the platform facilitates collaboration and efficiency in drug discovery processes.

4. Genomic Healthcare and Data Utilization
Kunihiro Nishimura from Tenkou provided insights on the role of genomic information in personalized medicine, underscoring the importance of data and AI to enhance cancer diagnostics and treatment pathways.

5. Intellectual Property and AI Strategy
Hiroshi Morita addressed the challenge of securing intellectual property in the fast-evolving landscape of drug discovery and biotechnology, proposing strategies for optimizing patent applications and managing innovations.

6. Legal Frameworks Around AI in Healthcare
This session focused on legal considerations and governance surrounding AI and data use in the biotechnology sector. Key legal experts outlined practical implications and the broader impact of emerging legislation on innovation and development.

7. Social Implementation of Vertical AI
Tomoyuki Hirai discussed the essential data foundations necessary for actualizing vertically integrated AI within corporate settings, emphasizing the need for secure data handling and integration across various business units.

8. Beyond Decarbonization: The Case for "Decarbonization"
Shinobu Kanno from BIRD INITIATIVE closed the discussions, presenting a visionary perspective on how redefining processes could lead to innovative solutions and business opportunities in the fields of drug discovery and biotechnology, through self-driving lab technologies.

Conclusion

The AI Agents × AX Forum successfully brought together thought leaders and professionals from the drug discovery and biotech fields to explore how corporate intelligence entwined with cutting-edge AI can pave the way for enhanced growth and innovation in these industries. Participants left equipped with new strategies and insights, amplifying their potential to harness data-driven decision-making in the rapidly changing landscape of biotechnology and pharmacology.